# UniXell Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unixell-biotechnology

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.unixell.com
- Total disclosed funding: $21M
- Latest round: Series A (Feb 11, 2026)
- Investors on record: 7

## About

Based in Shanghai, China and founded in 2021, Shanghai Yuesai Biotechnology Co., Ltd., trading as UniXell Biotechnology, is a developer of new generations of cell therapy drugs, focusing on the development of next-generation cell therapy drugs based on human pluripotent stem cell technology. It has an R&D centre of approximately 4,000 square meters and a GMP clean factory building. The founder, Dr. Yuejun Chen, graduated from the University of Wisconsin, Madison, and has worked at the Chinese Academy of Sciences. In February 2026, UniXell Biotechnology raised 50 million in series A+ funding from new investors Panlin Capital, Quancun Venture Capital, and Waigaoqiao Private Equity Fund.

The company utilizes a self-developed platform for technology research and product development in the field of stem cell therapy. The platform is a technology platform for human pluripotent stem cell preparation, culture, differentiation and gene editing. The company currently has five product pipelines under research and development. The R&D pipeline therapeutic areas include neurodegenerative diseases, rare diseases and tumors.

The company generates revenue by providing its proprietary cell therapy products and services.

The series A+ round of funding will be used to accelerate the clinical trials of the company's universal cell therapy pipeline for epilepsy and Parkinson's disease, and to further deepen the large-scale development and industrialization of innovative cell therapy drugs.

## Funding rounds

- Series A, Feb 11, 2026, $7.2M — Panlin Capital
- Series A, Nov 6, 2025 — Pudong Capital, Shanghai State-owned Capital Investment Leading Fund
- Series A, Jul 12, 2024 — CAS Venture Capital
- Series A, Apr 1, 2024, $14M — Pudong Capital
- Angel, Aug 25, 2021 — TF Capital, Shanhai Capital, GL Ventures

## Investors

- TF Capital — Angel
- Shanhai Capital (https://capitalatlas.ai/funds/shanhai-capital) — Angel
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Angel
- Pudong Capital (https://capitalatlas.ai/funds/pudong-capital) — Series A
- CAS Venture Capital (https://capitalatlas.ai/funds/cas-venture-capital) — Series A
- Shanghai State-owned Capital Investment Leading Fund (https://capitalatlas.ai/funds/shanghai-state-owned-capital-investment-leading-fund) — Series A
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series A